Cargando…

Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy

AIM: To assess the metabolic characteristics of non-obese metabolic dysfunction-associated fatty liver disease (MAFLD) compared with obese MAFLD and the relationship of MAFLD with diabetic peripheral neuropathy and diabetic retinopathy in patients with Type 2 diabetes mellitus (T2DM). METHODS: Data...

Descripción completa

Detalles Bibliográficos
Autores principales: Dang, Si-Wen, Gao, Lei, Li, Yu-Jun, Zhang, Ruo, Xu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566373/
https://www.ncbi.nlm.nih.gov/pubmed/37828942
http://dx.doi.org/10.3389/fmed.2023.1216412
_version_ 1785118910345904128
author Dang, Si-Wen
Gao, Lei
Li, Yu-Jun
Zhang, Ruo
Xu, Jing
author_facet Dang, Si-Wen
Gao, Lei
Li, Yu-Jun
Zhang, Ruo
Xu, Jing
author_sort Dang, Si-Wen
collection PubMed
description AIM: To assess the metabolic characteristics of non-obese metabolic dysfunction-associated fatty liver disease (MAFLD) compared with obese MAFLD and the relationship of MAFLD with diabetic peripheral neuropathy and diabetic retinopathy in patients with Type 2 diabetes mellitus (T2DM). METHODS: Data were obtained from 536 T2DM patients (355 women, 181 men; age 58.2 ± 12.0 years). We explored the difference in clinical characteristics between obese MAFLD (body mass index ≥25 kg/m(2)) and non-obese MAFLD (body mass index <25 kg/m(2)) in T2DM patients. One-way analysis of variance (ANOVA) was used to compare the means of continuous variables, and the Chi-squared test was used to compare the differences in frequencies of categorical variables. Logistic regression models were adopted to calculate odds ratios. RESULTS: The prevalence of MAFLD in hospitalized Chinese T2DM patients was calculated to be 42.7%. Both obese and non-obese MAFLD patients had higher levels of body mass index (BMI), waist circumfere nce, triglyceride, alanine aminotransferase, aspar tate aminotransferase, γ-glutamyltransferase, you nger age, higher prevalence of hyperlipidemia and shorter duration of T2DM and lower incidence of diabetic retinopathy, compared with participants with out MAFLD in the same weight group. Uric acid levels were positively correlated with the risk of MAFLD only in non-obese subjects but not in obese subjects. In non-obese patients with T2DM, a negative correlation was found between the prevalence of MAFLD and diabetic retinopathy. CONCLUSION: Even in non-obese patients with T2DM, BMI was found to be an independent risk factor for MAFLD. These findings support a more structured, risk-factor-based approach to MAFLD management, particularly in patients with T2DM. Non-obese MAFLD has unique results in metabolic characteristics and the correlation with diabetic retinopathy and diabetic peripheral neuropathy, which should be further explored.
format Online
Article
Text
id pubmed-10566373
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105663732023-10-12 Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy Dang, Si-Wen Gao, Lei Li, Yu-Jun Zhang, Ruo Xu, Jing Front Med (Lausanne) Medicine AIM: To assess the metabolic characteristics of non-obese metabolic dysfunction-associated fatty liver disease (MAFLD) compared with obese MAFLD and the relationship of MAFLD with diabetic peripheral neuropathy and diabetic retinopathy in patients with Type 2 diabetes mellitus (T2DM). METHODS: Data were obtained from 536 T2DM patients (355 women, 181 men; age 58.2 ± 12.0 years). We explored the difference in clinical characteristics between obese MAFLD (body mass index ≥25 kg/m(2)) and non-obese MAFLD (body mass index <25 kg/m(2)) in T2DM patients. One-way analysis of variance (ANOVA) was used to compare the means of continuous variables, and the Chi-squared test was used to compare the differences in frequencies of categorical variables. Logistic regression models were adopted to calculate odds ratios. RESULTS: The prevalence of MAFLD in hospitalized Chinese T2DM patients was calculated to be 42.7%. Both obese and non-obese MAFLD patients had higher levels of body mass index (BMI), waist circumfere nce, triglyceride, alanine aminotransferase, aspar tate aminotransferase, γ-glutamyltransferase, you nger age, higher prevalence of hyperlipidemia and shorter duration of T2DM and lower incidence of diabetic retinopathy, compared with participants with out MAFLD in the same weight group. Uric acid levels were positively correlated with the risk of MAFLD only in non-obese subjects but not in obese subjects. In non-obese patients with T2DM, a negative correlation was found between the prevalence of MAFLD and diabetic retinopathy. CONCLUSION: Even in non-obese patients with T2DM, BMI was found to be an independent risk factor for MAFLD. These findings support a more structured, risk-factor-based approach to MAFLD management, particularly in patients with T2DM. Non-obese MAFLD has unique results in metabolic characteristics and the correlation with diabetic retinopathy and diabetic peripheral neuropathy, which should be further explored. Frontiers Media S.A. 2023-09-27 /pmc/articles/PMC10566373/ /pubmed/37828942 http://dx.doi.org/10.3389/fmed.2023.1216412 Text en Copyright © 2023 Dang, Gao, Li, Zhang and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Dang, Si-Wen
Gao, Lei
Li, Yu-Jun
Zhang, Ruo
Xu, Jing
Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy
title Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy
title_full Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy
title_fullStr Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy
title_full_unstemmed Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy
title_short Metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy
title_sort metabolic characteristics of non-obese and obese metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus and its association with diabetic peripheral neuropathy and diabetic retinopathy
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566373/
https://www.ncbi.nlm.nih.gov/pubmed/37828942
http://dx.doi.org/10.3389/fmed.2023.1216412
work_keys_str_mv AT dangsiwen metaboliccharacteristicsofnonobeseandobesemetabolicdysfunctionassociatedfattyliverdiseaseintype2diabetesmellitusanditsassociationwithdiabeticperipheralneuropathyanddiabeticretinopathy
AT gaolei metaboliccharacteristicsofnonobeseandobesemetabolicdysfunctionassociatedfattyliverdiseaseintype2diabetesmellitusanditsassociationwithdiabeticperipheralneuropathyanddiabeticretinopathy
AT liyujun metaboliccharacteristicsofnonobeseandobesemetabolicdysfunctionassociatedfattyliverdiseaseintype2diabetesmellitusanditsassociationwithdiabeticperipheralneuropathyanddiabeticretinopathy
AT zhangruo metaboliccharacteristicsofnonobeseandobesemetabolicdysfunctionassociatedfattyliverdiseaseintype2diabetesmellitusanditsassociationwithdiabeticperipheralneuropathyanddiabeticretinopathy
AT xujing metaboliccharacteristicsofnonobeseandobesemetabolicdysfunctionassociatedfattyliverdiseaseintype2diabetesmellitusanditsassociationwithdiabeticperipheralneuropathyanddiabeticretinopathy